SYMQY (SymBio Pharmaceuticals) Total Assets: $24.80 Mil (As of Dec. 2025)


SYMQY SymBio Pharmaceuticals Ltd SYMQY
35 GF Score
Price $0.56
GF Value $0.48
! 6 Warning Signs
View Full Analysis

What is SymBio Pharmaceuticals Total Assets?

SymBio Pharmaceuticals SYMQY -12.42% 35 Total Assets is $24.80 Mil as of Dec. 2025. GuruFocus rates SYMQY with a GF Score™ of 35/100 and a GF Value™ of $0.48. The stock has 6 warning signs investors should review.

SymBio Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was $24.80 Mil.

During the past 12 months, SymBio Pharmaceuticals's average Total Assets Growth Rate was -2.10% per year. During the past 3 years, the average Total Assets Growth Rate was -38.10% per year. During the past 5 years, the average Total Assets Growth Rate was -24.80% per year. During the past 10 years, the average Total Assets Growth Rate was 4.70% per year.

During the past 13 years, SymBio Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 78.50%. The lowest was -39.70%. And the median was 19.70%.

Total Assets is connected with ROA %. SymBio Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2025 was -111.35%. Total Assets is also linked to Revenue through Asset Turnover. SymBio Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2025 was 0.08.

SymBio Pharmaceuticals  (OTCPK:SYMQY) Total Assets Explanation

Total Assets is connected with ROA %.

SymBio Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-31.056/( (30.975+24.804)/ 2 )
=-31.056/27.8895
=-111.35 %

Note: The Net Income data used here is four times the quarterly (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

SymBio Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=2.16/( (30.975+24.804)/ 2 )
=2.16/27.8895
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

SymBio Pharmaceuticals Total Assets Related Terms

SymBio Pharmaceuticals Total Assets Historical Data

* Premium members only.

The historical data trend for SymBio Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SymBio Pharmaceuticals Total Assets Chart

SymBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 74.26 77.33 56.75 32.30 24.80

SymBio Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.31 28.65 30.98 24.80 18.57
SYMQY
35GF Score
SymBio Pharmaceuticals Ltd SYMQY
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SymBio Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

SymBio Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=8.159+16.645
=24.80

SymBio Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=8.159+16.645
=24.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $24.80 Mil mean?
SymBio Pharmaceuticals (SYMQY) has a Total Assets of $24.80 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on SymBio Pharmaceuticals and its competitors.
Is SymBio Pharmaceuticals' Total Assets too high?
SymBio Pharmaceuticals' current Total Assets is $24.80 Mil. Overall, SymBio Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Total Assets compare to ZTS and UTHR?
SymBio Pharmaceuticals' Total Assets of $24.80 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on SymBio Pharmaceuticals and its competitors. SymBio Pharmaceuticals's current Total Assets is $24.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
SymBio Pharmaceuticals (SYMQY) has a current Total Assets of $24.80 Mil. The stock's GF Value™ is $0.48, compared to a current price of $0.56 — trading 16.2% above its estimated fair value. The current Total Assets is $24.80 Mil. SymBio Pharmaceuticals' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For SymBio Pharmaceuticals (SYMQY), the current Total Assets is $24.80 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SymBio Pharmaceuticals (SYMQY) Overvalued in 2026?

Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued. The current stock price of $0.56 is trading 16.2% above its estimated GF Value™ of $0.48.

Key valuation signals for SYMQY:

  • Total Assets: $24.80 Mil
  • GF Value™: $0.48 vs. price of $0.56 (16.2% above fair value)
  • GF Score™: 35/100 with 6 warning signs

No single metric tells the full story. See the SYMQY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SymBio Pharmaceuticals Business Description

Other Exchanges 4582:Japan
Address 1-28 Toranomon 4-chome, 7th Floor, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
35GF Score

Get the complete analysis for SYMQY

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price
$0.48
GF Value